Blood Clot Formation
18
-
Upload
amena-dorsey -
Category
Documents
-
view
38 -
download
1
description
Blood Clot Formation. ATLAS ACS 2—TIMI 51 Design. ATLAS-2 Patients With Biomarker Elevation, n = 12,626. ATLAS-2 Patients With Biomarker Elevation, n = 12,626. APPRAISE-2. ATLAS-ACS TIMI 46. Newer Antiplatelet Agents. WOEST Efficacy End Points. WOEST Bleeding Events. - PowerPoint PPT Presentation
Transcript of Blood Clot Formation
![Page 1: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/1.jpg)
![Page 2: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/2.jpg)
Blood Clot Formation
![Page 3: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/3.jpg)
ATLAS ACS 2—TIMI 51Design
![Page 4: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/4.jpg)
![Page 5: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/5.jpg)
![Page 6: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/6.jpg)
ATLAS-2Patients With Biomarker Elevation, n =
12,626
![Page 7: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/7.jpg)
ATLAS-2Patients With Biomarker Elevation, n =
12,626
![Page 8: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/8.jpg)
APPRAISE-2
![Page 9: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/9.jpg)
ATLAS-ACS TIMI 46
![Page 10: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/10.jpg)
Newer Antiplatelet Agents
![Page 11: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/11.jpg)
WOESTEfficacy End Points
![Page 12: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/12.jpg)
WOESTBleeding Events
![Page 13: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/13.jpg)
![Page 14: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/14.jpg)
![Page 15: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/15.jpg)
![Page 16: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/16.jpg)
![Page 17: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/17.jpg)
![Page 18: Blood Clot Formation](https://reader035.fdocuments.in/reader035/viewer/2022062314/56812cab550346895d915bbd/html5/thumbnails/18.jpg)